Human Apolipoprotein C3,apo-C3ELISA Kit

Code CSB-E13760h
Size 96T,5×96T,10×96T
Trial Size 24T ELISA kits trial application
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Description

This Human APOC3 ELISA Kit was designed for the quantitative measurement of Human APOC3 protein in serum, plasma, tissue homogenates. It is a Competitive ELISA kit, its detection range is 15.6 ng/mL-1000 ng/mL and the sensitivity is 3.9 ng/mL.

Target Name apolipoprotein C-III
Alternative Names APOC3 ELISA Kit; APO C3 ELISA Kit; Apo CIII ELISA Kit; Apo-CIII ELISA Kit; APOC 3 ELISA Kit; ApoC III ELISA Kit; ApoC-III ELISA Kit; APOC3 ELISA Kit; APOC3_HUMAN ELISA Kit; ApoCIII ELISA Kit; Apolipoprotein C III ELISA Kit; Apolipoprotein C-III ELISA Kit; Apolipoprotein C3 ELISA Kit; ApolipoproteinCIII ELISA Kit; MGC150353 ELISA Kit
Abbreviation APOC3
Uniprot No. P02656
Species Homo sapiens (Human)
Sample Types serum, plasma, tissue homogenates
Detection Range 15.6 ng/mL-1000 ng/mL
Sensitivity 3.9 ng/mL
Assay Time 1-5h
Sample Volume 50-100ul
Detection Wavelength 450 nm
Research Area Metabolism
Assay Principle quantitative
Measurement Competitive
Precision
Intra-assay Precision (Precision within an assay): CV%<8%
Three samples of known concentration were tested twenty times on one plate to assess.
Inter-assay Precision (Precision between assays): CV%<10%
Three samples of known concentration were tested in twenty assays to assess.
Linearity
To assess the linearity of the assay, samples were spiked with high concentrations of human apo-C3 in various matrices and diluted with the Sample Diluent to produce samples with values within the dynamic range of the assay.
SampleSerum(n=4)
1:100Average %95
Range %87-99
1:200Average %89
Range %81-94
1:400Average %101
Range %91-105
1:800Average %100
Range %90-105
Recovery
The recovery of human apo-C3 spiked to levels throughout the range of the assay in various matrices was evaluated. Samples were diluted prior to assay as directed in the Sample Preparation section.
Sample TypeAverage % RecoveryRange
Serum (n=5) 9387-98
EDTA plasma (n=4)9790-103
Typical Data
These standard curves are provided for demonstration only. A standard curve should be generated for each set of samples assayed.
ng/mlOD1OD2Average
10000.080 0.085 0.083
5000.126 0.123 0.125
2500.200 0.209 0.205
1250.363 0.370 0.367
62.50.587 0.612 0.600
31.250.804 0.823 0.814
15.61.112 1.164 1.138
01.944 1.878 1.911
ELISA Data Analysis Watch ELISA data processing video & download Curve Expert if needed
Troubleshooting
and FAQs
ELISA kit FAQs
Storage Store at 2-8°C. Please refer to protocol.
Lead Time 3-5 working days

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

Function
(From Uniprot)
Component of triglyceride-rich very low density lipoproteins (VLDL) and high density lipoproteins (HDL) in plasma. Plays a multifaceted role in triglyceride homeostasis. Intracellularly, promotes hepatic very low density lipoprotein 1 (VLDL1) assembly and secretion; extracellularly, attenuates hydrolysis and clearance of triglyceride-rich lipoproteins (TRLs). Impairs the lipolysis of TRLs by inhibiting lipoprotein lipase and the hepatic uptake of TRLs by remnant receptors. Formed of several curved helices connected via semiflexible hinges, so that it can wrap tightly around the curved micelle surface and easily adapt to the different diameters of its natural binding partners.
Gene References into Functions
  1. ApoCIII may mediate the effects of ANGPTL8 on triglyceride metabolism. PMID: 30021607
  2. The S2 allele of the SstI polymorphism in the apoC3 gene is associated with plasma apoCIII levels in the Li population. In combination with unfavorable lipid profiles, this might contribute to susceptibility to atherosclerosis. PMID: 29162127
  3. Data indicate effects of a loss-of-function Ala43Thr substitution in apolipoprotein C3 (APOC3) rs147210663. PMID: 29237685
  4. the present study demonstrates major modifications of the proteome in patients with cerebral lacunar infarction(LACI). The ApoC-III enrichment of the HDL of patients with cerebral lacunar infarction may cause a reduction in the anti-inflammatory ability of HDL, which may contribute to the progression of the disease PMID: 29115584
  5. C3(QK) variant is a gain-of-function mutation that can stimulate VLDL1 production, through enhanced DNL PMID: 28887372
  6. Review/Meta-analysis: APOC3 polymorphisms were not association with increased risk of ischemic stroke PMID: 28865324
  7. rs4225 in the 3'-UTR of APOC3 might contribute to the risk of coronary heart disease by interfering with miR-4271 binding. PMID: 27624799
  8. APOC3 modulates HDL structure and function, while it selectively promotes BAT metabolic activation PMID: 28701354
  9. apoC-III potently inhibits triglyceride hydrolysis when LPL is bound to GPIHBP1 PMID: 28694296
  10. apolipoprotein C3 and atherosclerosis PMID: 28441154
  11. intestinal apoC-III overexpression results in the secretion of smaller, less dense chylomicron particles along with reduced triacylglycerol secretion from the intestine PMID: 28159868
  12. Aromatic residues in the C terminus of apolipoprotein C-III mediate lipid binding and LPL inhibition PMID: 28159869
  13. No evidence that APOC3 3'UTR variant SstI modulates expression of liver/intestinal miRNAs in hypertriglyceridemia. PMID: 27794214
  14. A rare variant in APOC3(rs138326449) has been associated with triglyceride, very low-density lipoprotein, and high-density lipoprotein levels, as well as risk of coronary heart disease. Effects are unlikely to be solely predictable by the action of APOC3 through LPL. PMID: 27114411
  15. both human APOC3 A43T heterozygotes and mice expressing human APOC3 A43T display markedly reduced circulating apoC-III levels. In mice, this reduction is due to impaired binding of A43T apoC-III to lipoproteins and accelerated renal catabolism of free apoC-III. PMID: 28825717
  16. Gene-level meta-analysis with other studies reporting burden signals at APOC3 provides robust evidence for a replicable cardioprotective rare variant aggregation PMID: 27146844
  17. studied the associations of apoC-III, endothelial function and diabetic peripheral neuropathy PMID: 28641786
  18. Plasma levels of proprotein convertase subtilisin/kexin type 9 (PCSK9), apolipoprotein C-III (apoC3) and small dense low density lipoprotein cholesterol (sdLDL-C) showed significant interactions with current dyslipidemias, and were predictive in the screening. PMID: 27713142
  19. Novel sequencing techniques are detecting rare variants with larger effect sizes (eg, APOC3) , which may further improve on Cardiovascular disease risk prediction. PMID: 27650930
  20. The APOC3 rs2070666 A allele is a risk factor for NAFLD independent of obesity, dyslipidemia, and PNPLA3 rs738409, and it might contribute to increased liver fat content in Chinese Han population. PMID: 27059980
  21. plasma levels significantly associated with the development and severity of metabolic syndrome PMID: 28245894
  22. ApoC-III levels are significantly associated with incident coronary artery disease risk. Elevated levels of remnant lipoproteins, small dense low-density lipoprotein, and low-grade inflammation may explain this association. PMID: 28473441
  23. The authors findings confirm an association of APOC3 with gout. PMID: 27094595
  24. Accumulating evidence indicates that apolipoprotein C-III is a multifaceted protein which not only regulates triglyceride metabolism, but also participates in the atherosclerotic lesion formation and several other pathological processes involved in atherosclerosis. PMID: 27770802
  25. Our results showed that APOC3 was closely associated with the inflammatory process in ECs, and that this process was characterized by the increased expression of TNF-alpha. Inflammatory processes further disrupted the tight junctions (TJs) between HUVECs by causing increased expression of JAM-1. PMID: 27619170
  26. review of its clinical implications and targeted therapies[review] PMID: 27318213
  27. Transgenic mice expressing human APOC3in the C57BL/6J background have been described. The study found that hypertriglyceridemia per se is not an independent risk factor for beta cell dysfunction in ApoC3 transgenic mice. PMID: 27226540
  28. ApoA-1 and ApoC-III may be used as differentiating and predictive markers for SCLC [ small cell lung cancer ]. PMID: 26996551
  29. The results of our meta-analysis point to a strong link between both APOA5 -1131T>C and APOC3 -455T>C polymorphisms and an increased risk of coronary heart disease . PMID: 26782469
  30. HDL-apoCIII has a significant and positive association with coronary heart disease . PMID: 26452348
  31. APOA5 -1131 T > C and APOC3 -455 T > C SNPs may play potent roles in the development and progression of coronary heart disease. (Meta-analysis) PMID: 26387083
  32. D25V apolipoprotein C-III is a new human amyloidogenic protein and the first conferring cardioprotection. PMID: 26790392
  33. The current body of literature includes several methodologically sound studies that together provide consistent evidence for an association of cardiovascular events with blood apoC-III level in total plasma or in VLDL and LDL. PMID: 26228667
  34. 3238C>G polymorphism of ApoC3 gene appears to augment the propensity to develop T2DM, while -482C>T to negatively affect lipid metabolism in Saudi subjects. PMID: 26247234
  35. Data suggest that apolipoprotein C-III (ApoCIII) adopts an alternate helical conformation on the bilayer which could have functional implications. PMID: 26301570
  36. Lipoprotein associated phospholipase A2 activity and apolipoprotein C3 loss-of-function variants are involved in cardiovascular disease PMID: 26117401
  37. genetic variants associated with elevated triglycerides and VLDL and risk of intracerebral hemorrhage PMID: 25994187
  38. meta-analysis demonstrates significant association between rs5128 polymorphism and higher levels of APOC3, TG, TC and LDL-C PMID: 25928461
  39. ApoC3 Sst I and T-455C polymorphisms might be associated with coronary heart disease risk. PMID: 24430880
  40. The objective of this study was to evaluate the reliability of MALDI-TOF mass spectrometry of apoC-III for the detection and characterization of congenital disorders of glycosylation-associated O-glycan defects. PMID: 25641685
  41. APOC3 loss-of- function mutation carriers had reduced plasma triglycerides, higher HDL-C,and a decreased burden of coronary arterial calcification. PMID: 26516010
  42. In examined Kyrgyz ethnic population the most frequent was heterozygous TC genotype of T455C polymorphism of apo C-III. PMID: 26625519
  43. In persons with T2DM, increased plasma ApoC-III is associated with higher triglycerides, less favorable cardiometabolic phenotypes, and higher coronary artery calcification, a measure of subclinical atherosclerosis. PMID: 26069232
  44. Obesity favors apolipoprotein E- and C-III-containing high density lipoprotein subfractions associated with risk of heart disease. PMID: 24966274
  45. The polymorphism T-455C in APOC3 gene and elevated serum triglycerides were associated with NAFLD. However, we did not find a significant association of C-482T polymorphism (rs2854117) of APOC3 gene with NAFLD. PMID: 25319715
  46. these results suggest that plasma apoA-I could be a sensitive Alzheimer's disease biomarker and individuals with low plasma levels of apoC-III are at risk for Alzheimer's disease. PMID: 24685634
  47. APOC3 R19X allele participants had approximately half the triglyceride levels, >20% higher high-density lipoprotein cholesterol levels, and lower low-density lipoprotein cholesterol levels compared with noncarrier participants. PMID: 25363704
  48. The APOC3 3238 G allele might contribute to an increased risk of coronary artery disease as a result of its effect on triglycerides and VLDL-cholesterol metabolism. PMID: 25380998
  49. Confirming the negative role of APOC-III in TG metabolism can be used as therapeutic target for the management of hypertriglyceridemia and reduction of ischemic cardiovascular events. PMID: 25994465
  50. APOC3 (-455T>C) genetic variation is involved in the susceptibility to developing NAFLD in the Southern Chinese Han population. PMID: 25320541

Show More

Hide All

Involvement in disease Hyperalphalipoproteinemia 2 (HALP2)
Subcellular Location Secreted.
Protein Families Apolipoprotein C3 family
Tissue Specificity Liver.
Database Links

HGNC: 610

OMIM: 107720

KEGG: hsa:345

STRING: 9606.ENSP00000227667

UniGene: Hs.73849

Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
Address
7505 Fannin St. Ste 610-312, Houston, TX 77054, USA
Join Us with

Subscribe newsletter

Leave a message

© 2007-2022 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1